Compass Financial Services Inc Purchases Shares of 65 Eli Lilly and Company (NYSE:LLY)

Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 65 shares of the company’s stock, valued at approximately $50,000.

Other hedge funds have also modified their holdings of the company. Newbridge Financial Services Group Inc. lifted its stake in Eli Lilly and Company by 7.6% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 5,310 shares of the company’s stock valued at $4,099,000 after acquiring an additional 375 shares in the last quarter. Kestra Private Wealth Services LLC raised its holdings in shares of Eli Lilly and Company by 19.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 39,354 shares of the company’s stock valued at $30,381,000 after purchasing an additional 6,386 shares during the last quarter. Essex LLC raised its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Essex LLC now owns 1,980 shares of the company’s stock valued at $1,529,000 after purchasing an additional 30 shares during the last quarter. Quotient Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 4.8% in the fourth quarter. Quotient Wealth Partners LLC now owns 3,154 shares of the company’s stock worth $2,435,000 after purchasing an additional 145 shares in the last quarter. Finally, Northeast Investment Management boosted its holdings in Eli Lilly and Company by 4.3% during the fourth quarter. Northeast Investment Management now owns 53,478 shares of the company’s stock worth $41,285,000 after purchasing an additional 2,226 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 1.1 %

Shares of LLY stock opened at $868.57 on Tuesday. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a market capitalization of $824.55 billion, a PE ratio of 74.17, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. The firm has a 50 day moving average price of $789.87 and a two-hundred day moving average price of $843.19. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, analysts predict that Eli Lilly and Company will post 23.33 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is 44.41%.

Eli Lilly and Company announced that its Board of Directors has authorized a stock repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Wolfe Research initiated coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Finally, Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.